Loading...
XKRX
237690
Market cap1.51bUSD
Dec 05, Last price  
118,000.00KRW
1D
0.08%
1Q
20.41%
Jan 2017
163.10%
IPO
168.18%
Name

ST Pharm Co Ltd

Chart & Performance

D1W1MN
XKRX:237690 chart
P/E
63.94
P/S
8.11
EPS
1,845.51
Div Yield, %
Shrs. gr., 5y
0.89%
Rev. gr., 5y
24.03%
Revenues
273.75b
-3.94%
138,052,135,210200,361,532,900202,800,435,36297,738,455,80593,256,824,542124,108,663,975165,641,947,051249,321,677,973284,991,652,400273,751,343,000
Net income
34.71b
+77.27%
25,188,825,08061,425,867,57244,996,926,435-9,267,935,047-18,528,696,163-12,147,164,4473,312,124,53018,000,015,28019,581,189,74834,711,731,000
CFO
109.45b
+8,329.82%
35,821,583,86049,589,524,93255,593,624,79512,012,442,144-28,949,923,284-20,701,040,1587,648,753,9537,456,124,8071,298,383,430109,451,358,000
Dividend
Dec 27, 2023500 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea. The company offers chemistry manufacturing control (CMC) services, which includes analytical method development; in-house reference standard testing; analytical method qualification/validation; analytical characterization; and CMC documentation. It also provides oligonucleotide based products, such as antisense, siRNA, miRNA, aptamer, CpG, decoy, and other products; and monomer/phosphoramidite. In addition, the company offers generic APIs for anti-cancer, anti-coagulant, anti-fungal, anti-hyperlipidemia, anti-hypertensive, anti-tuberculosis, asthma, COPD, cough suppressant, diabetes mellitus, epilepsy, hepatitis B, and erectile dysfunction medicines, as well as MRI contrast agents. Further, it provides 2nd battery, electronic materials, and polymer catalysts. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 and is based in Seoul, South Korea.
IPO date
Jun 23, 2016
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT